Effect of 3,4-diaminopyridine at the murine neuromuscular junction

Fiona Ng, Diana C. Lee, Leah A. Schrumpf, Mary E. Mazurek, Victoria Lee Lo, Sharleen K. Gill, Ricardo A Maselli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes.

Original languageEnglish (US)
JournalMuscle and Nerve
DOIs
StateAccepted/In press - 2016

Fingerprint

Neuromuscular Junction
Synaptic Vesicles
Neuromuscular Junction Diseases
Congenital Myasthenic Syndromes
Lambert-Eaton Myasthenic Syndrome
Microelectrodes
Diaphragm
Acetylcholine
3,4-diaminopyridine
Muscles

Keywords

  • 3,4-diaminopyridine
  • Congenital myasthenic syndromes
  • Endplate potential
  • Lambert-Eaton myasthenic syndrome
  • Neuromuscular junction
  • Quantal release

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Ng, F., Lee, D. C., Schrumpf, L. A., Mazurek, M. E., Lee Lo, V., Gill, S. K., & Maselli, R. A. (Accepted/In press). Effect of 3,4-diaminopyridine at the murine neuromuscular junction. Muscle and Nerve. https://doi.org/10.1002/mus.25208

Effect of 3,4-diaminopyridine at the murine neuromuscular junction. / Ng, Fiona; Lee, Diana C.; Schrumpf, Leah A.; Mazurek, Mary E.; Lee Lo, Victoria; Gill, Sharleen K.; Maselli, Ricardo A.

In: Muscle and Nerve, 2016.

Research output: Contribution to journalArticle

Ng, Fiona ; Lee, Diana C. ; Schrumpf, Leah A. ; Mazurek, Mary E. ; Lee Lo, Victoria ; Gill, Sharleen K. ; Maselli, Ricardo A. / Effect of 3,4-diaminopyridine at the murine neuromuscular junction. In: Muscle and Nerve. 2016.
@article{ae1ba93e9066467e864fda28fd9c1ccb,
title = "Effect of 3,4-diaminopyridine at the murine neuromuscular junction",
abstract = "Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000{\%} increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes.",
keywords = "3,4-diaminopyridine, Congenital myasthenic syndromes, Endplate potential, Lambert-Eaton myasthenic syndrome, Neuromuscular junction, Quantal release",
author = "Fiona Ng and Lee, {Diana C.} and Schrumpf, {Leah A.} and Mazurek, {Mary E.} and {Lee Lo}, Victoria and Gill, {Sharleen K.} and Maselli, {Ricardo A}",
year = "2016",
doi = "10.1002/mus.25208",
language = "English (US)",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Effect of 3,4-diaminopyridine at the murine neuromuscular junction

AU - Ng, Fiona

AU - Lee, Diana C.

AU - Schrumpf, Leah A.

AU - Mazurek, Mary E.

AU - Lee Lo, Victoria

AU - Gill, Sharleen K.

AU - Maselli, Ricardo A

PY - 2016

Y1 - 2016

N2 - Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes.

AB - Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes.

KW - 3,4-diaminopyridine

KW - Congenital myasthenic syndromes

KW - Endplate potential

KW - Lambert-Eaton myasthenic syndrome

KW - Neuromuscular junction

KW - Quantal release

UR - http://www.scopus.com/inward/record.url?scp=84994495865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994495865&partnerID=8YFLogxK

U2 - 10.1002/mus.25208

DO - 10.1002/mus.25208

M3 - Article

C2 - 27251582

AN - SCOPUS:84994495865

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

ER -